Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 762

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 762
---
 would use in pricing the asset or liability. |

The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2024 and December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

| Assets:                           |     | As ofDecember 31,2024 |           |     | QuotedPrices inActiveMarkets(Level 1) |   |     | SignificantOtherObservableInputs(Level 2) |           |     | SignificantOtherUnobservable 
 Inputs(Level 3)              |   |
|:----------------------------------|:----|:----------------------|----------:|:----|:--------------------------------------|:--|:----|:------------------------------------------|----------:|:----|:-----------------------------|:--|
| Investments held in Trust Account |     | $                     | 9,021,005 |     | $                                     | — |     | $                                         | 9,021,005 |     |                              | — |

| Assets:                           |     | As ofDecember 31,2023 |            |     | QuotedPrices inActiveMarkets(Level 1) |            |     | SignificantOtherObservableInputs(Level 2) |   |     | SignificantOtherUnobservableInputs(Level 3) |   |
|:----------------------------------|:----|:----------------------|-----------:|:----|:--------------------------------------|-----------:|:----|:------------------------------------------|:--|:----|:--------------------------------------------|:--|
| Investments held in Trust Account |     | $                     | 50,477,963 |     | $                                     | 50,477,963 |     | $                                         | — |     |                                             | — |

NOTE 9 – SEGMENT INFORMATION ASC Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker, or group, in deciding how to allocate resources and assess performance. The Company has adopted the guidance in ASU 2023-07,Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, in the accompanying financial statements using the retrospective method of adoption. F-31

The Company’s chief operating decision maker has been identified as the